By Bart L. Scott, MD

University of Washington School of Medicine and Fred Hutchinson Cancer Center

Professor of Medicine in the Division of Oncology at the University of Washington School of Medicine and a physician-scientist at Fred Hutchinson Cancer Center in Seattle, Washington.

Published Articles (1)

The Venetoclax Revolution in AML, and Its Limits in MDS: What the PARADIGM and VERONA Trials Mean for Practice

May 29, 2026

The PARADIGM and VERONA trials tell two very different stories about venetoclax in myeloid malignancies—a promising shift in AML treatment and a sobering setback in MDS. A leading expert breaks down both.